Latanoprostene Bunod Ophthalmic
Latanoprostene bunod ophthalmic is a prostaglandin analog eye drop used to lower eye pressure in people with open-angle glaucoma or ocular hypertension.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Vyzulta is a once-daily evening eye drop from the prostaglandin family, the usual first choice for open-angle glaucoma and ocular hypertension (high eye pressure), and it lowers pressure by helping fluid drain through both of the eye's outflow routes; it has been on the U.S. market since about 2017 and is still brand-only. Most people tolerate it well, and red-looking eyes and a brief sting as the drop goes in are the usual complaints. The one thing to watch for is a slow, likely permanent browning of the iris (the colored part of the eye), so keep up with your eye exams.
Clinical pearls
- Use it once each evening, never more often, and space it at least 5 minutes from any other glaucoma drop.
- Take contact lenses out first, since it contains benzalkonium chloride, and wait 15 minutes before putting them back in.
- Eyelashes may grow longer and thicker and eyelid skin may darken, though the lash changes usually fade after stopping.
- Keep the dropper tip from touching your eye or fingers, because a contaminated bottle can cause a serious corneal infection.
Patient information guide A plain-language walkthrough of Latanoprostene Bunod Ophthalmic, written from its FDA label.
What Latanoprostene Bunod Ophthalmic is used for
▾
Latanoprostene bunod ophthalmic is used to lower pressure inside the eye.
- Open-angle glaucoma
- Ocular hypertension (high eye pressure)
Vyzulta (0.024% eye drops) is the product covered here.
How Latanoprostene Bunod Ophthalmic works
▾
Latanoprostene bunod is a prostaglandin analog. It is thought to lower eye pressure by increasing the outflow of aqueous humor, the fluid inside the eye. It helps fluid drain through both the trabecular meshwork and the uveoscleral routes.
Eye pressure is a major risk factor for glaucoma getting worse. Lowering it reduces the risk of visual field loss.
Latanoprostene Bunod Ophthalmic dosage
▾
Vyzulta is used as one drop in the affected eye(s) once a day in the evening. Do not use it more than once daily, since more frequent use may reduce its pressure-lowering effect.
- If you use other eye pressure drops, space each product at least 5 minutes apart.
- Remove contact lenses first. You can put them back in after 15 minutes.
Follow your prescriber's directions and the label.
Dosing details from the FDA-approved label
From the Latanoprostene Bunod Ophthalmic prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Reduction of intraocular pressure (affected eye(s))
- One drop in the conjunctival sac of the affected eye(s) once daily in the evening
- Maximum: Do not administer more than once daily
- If used with other topical ophthalmic drug products to lower intraocular pressure, administer each at least five (5) minutes apart
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening. Do not administer VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure lowering effect. If VYZULTA is to be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure, administer each drug product at least five (5) minutes apart. One drop in the affected eye(s) once daily in the evening. ( 2 )
Read the full Dosage and Administration section on DailyMed →
Latanoprostene Bunod Ophthalmic side effects
▾
The most common side effects are in the eye.
Common side effects
- Eye redness (conjunctival hyperemia)
- Eye irritation
- Eye pain
- Pain when the drop goes in
- Eye redness (conjunctival hyperemia): about 6%
- Eye irritation: about 4%
- Eye pain: about 3%
- Pain when the drop goes in: about 2%
When to get medical help
- Call your doctor if you have eye pain, redness, or irritation that is severe or doesn't settle, or if it bothers you enough that you want to stop the drops.
- Call your doctor if you have blurred vision or a feeling that something is in your eye.
- Tell your doctor if you notice your iris (the colored part of the eye) getting browner. This change may be permanent.
- Call your doctor if you notice signs of eye infection or inflammation, especially if you have an existing eye surface problem.
About 0.6% of people stopped treatment because of eye side effects. Contact your doctor about severe or lasting eye symptoms, blurred vision, or a feeling of something in the eye.
Latanoprostene Bunod Ophthalmic warnings and precautions
▾
- Pigmentation: the iris and the skin around the eye can darken. Iris changes are likely permanent.
- Eyelash changes: lashes may grow longer, thicker, and more numerous. This usually reverses after stopping.
- Eye inflammation: use caution with a history of iritis or uveitis. Generally avoid it with active inflammation.
- Macular edema: swelling of the retina has been reported with this drug class. Use caution if you have risk factors.
- Bacterial keratitis: multiple-dose bottles can become contaminated, especially in people with corneal disease or damaged eye surface.
- Contact lenses: remove them before use because of benzalkonium chloride.
Latanoprostene Bunod Ophthalmic interactions
▾
The label gives one practical point about combining eye products.
- Other eye pressure-lowering drops: use each at least 5 minutes apart.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Latanoprostene Bunod Ophthalmic
▾
- No contraindications are listed.
- Tell your doctor about any history of eye inflammation, cataract surgery or lens problems, or risk factors for macular edema.
- Pregnancy: no human data. Animal studies showed miscarriage and fetal harm.
- Breastfeeding: no data. Your doctor will weigh benefits and risks.
- Children 16 and younger: not recommended.
- Older adults: no overall differences in safety or effectiveness.
What Latanoprostene Bunod Ophthalmic does in the body
▾
Eye pressure starts to drop about 1 to 3 hours after the first dose. The maximum effect is reached after about 11 to 13 hours in eyes with high pressure.
How your body processes Latanoprostene Bunod Ophthalmic
▾
After it goes into the eye, latanoprostene bunod is quickly broken down into latanoprost acid (the active part) and butanediol mononitrate. Very little reaches the bloodstream. Latanoprost acid peaked in the blood at about 5 minutes and fell below measurable levels in most people within 15 minutes. The liver breaks down latanoprost acid that reaches the blood.
How to store Latanoprostene Bunod Ophthalmic
▾
Unopened bottle should be stored refrigerated at 2°C to 8°C (36°F to 46°F). stored at 2°C to 25°C (36°F to 77°F) for 8 weeks. Protect from light.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Latanoprostene Bunod Ophthalmic: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Latanoprostene Bunod Ophthalmic — the kind of thing our pharmacy team would talk through with you at the counter.
What is this eye drop for?
▾
How and when do I use it?
▾
Can I wear my contact lenses?
▾
What side effects should I expect?
▾
Will it change my eye color?
▾
Is it safe in pregnancy or for kids?
▾
Is Latanoprostene Bunod Ophthalmic available over the counter?
▾
When was Latanoprostene Bunod Ophthalmic first available?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Latanoprostene Bunod Ophthalmic on HelloPharmacist
Latanoprostene Bunod Ophthalmic forms and strengths (how it comes)
Latanoprostene Bunod Ophthalmic is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Latanoprostene Bunod Ophthalmic inactive ingredients by manufacturer.
Eye drops
How this form is used
- Vyzulta is used to reduce eye pressure in people with open-angle glaucoma or ocular hypertension.
- Vyzulta is dosed as one drop in the affected eye(s) once daily in the evening.
- Do not use Vyzulta more than once daily.
- If using Vyzulta with other eye pressure drops, wait at least 5 minutes between them.
- Remove contact lenses before using Vyzulta and wait 15 minutes before reinserting them.
Latanoprostene Bunod Ophthalmic on the U.S. market: products, makers and brands
How Latanoprostene Bunod Ophthalmic appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 1 Latanoprostene Bunod Ophthalmic product record with the FDA, mostly as eye drops; the earliest marketing or approval year on record is 2017. Brand names on the directory include Vyzulta; the rest are generics.
How widely Latanoprostene Bunod Ophthalmic is used (Medicaid data)
A general measure of how commonly Latanoprostene Bunod Ophthalmic is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Latanoprostene Bunod Ophthalmic is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Latanoprostene Bunod Ophthalmic prescribed? Of the 1,601 medications we measure, Latanoprostene Bunod Ophthalmic ranks #876 by Medicaid prescriptions — more than 45% of them.
Utilization by Latanoprostene Bunod Ophthalmic product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
latanoprostene bunod 0.24 MG/ML Ophthalmic Solution
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1988394
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Latanoprostene Bunod Ophthalmic, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 6 listed Latanoprostene Bunod Ophthalmic NDCs with Medicaid activity.
Compare Latanoprostene Bunod Ophthalmic products
A representative set of FDA-listed product records for Latanoprostene Bunod Ophthalmic — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Eye drops | ||||
| 0.24 mg/mL | Ophthalmic | Bausch & Lomb Incorporated | NDA | View NDC → |
Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Latanoprostene Bunod Ophthalmic NDCs →
Latanoprostene Bunod Ophthalmic side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Latanoprostene Bunod Ophthalmic — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Latanoprostene Bunod Ophthalmic in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Latanoprostene Bunod Ophthalmic FDA approval history
How Latanoprostene Bunod Ophthalmic went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Latanoprostene Bunod Ophthalmic recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Latanoprostene Bunod recalls since July 2021.
✅No Latanoprostene Bunod recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1988390 1 dose form · 1 strength
-
Dose form (SCDF) Ophthalmic Solution RxCUI 1988393In current FDA listingsClinical drug / strength (SCD) 0.24 MG/MLRxCUI 1988394
Look up RxCUI 1988390 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Latanoprostene Bunod Ophthalmic supply and shortage status
Whether Latanoprostene Bunod Ophthalmic is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Latanoprostene Bunod Ophthalmic costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Solution/ Drops · Ophthalmic | 0.24 mg/mL | $102.25–$102.29 per mL | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Latanoprostene Bunod Ophthalmic brand names
Latanoprostene Bunod Ophthalmic is sold under one brand name in the FDA directory — Vyzulta. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Latanoprostene Bunod Ophthalmic: manufacturers and labelers
One company lists Latanoprostene Bunod Ophthalmic products with the FDA. By number of product records, the largest are Bausch & Lomb Incorporated. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Latanoprostene Bunod Ophthalmic drug class (RxNorm)
Latanoprostene Bunod Ophthalmic belongs to the Prostaglandin analogues class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Latanoprostene Bunod Ophthalmic page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Bausch & Lomb Incorporated is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →